A Study of CTD402 in T-ALL/LBL Patients
Recruiting now · Phase 1/Phase 2
Conditions studied: Acute Lymphocytic Leukemia Refractory, Lymphoma, Lymphoblastic
In brief
The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 12 will be eligible to participate. Participants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL. Patients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.
Key facts
- Study ID
- NCT07070219
- Run by
- Imviva Bio
- People needed
- 54
- Starts
- 2025-10-07
- Expected to finish
- 2028-12-30
- Last updated by the study team
- 2026-02-05
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Montefiore Einstein Comprehensive Cancer Center — The Bronx, New York, United States (enrolling)
- Sarah Cannon Research Insitute — Nashville, Tennessee, United States (enrolling)
- Stanford University — Palo Alto, California, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- Colorado Blood Cancer Institute — Denver, Colorado, United States
- University of Chicago — Chicago, Illinois, United States
- Mayo Clinic - Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.